摘要
研究目的:
研究C-erbB-2和VEGF在大肠癌肝转移灶和原发灶中的表达情况,分析两者在肝转移灶和大肠癌原发灶中表达是否存在差异,探讨其表达的规律性,分析其阳性表达与临床病理特征以及预后的关系。
材料与方法:
收集2000～2007年间复旦大学肿瘤医院外科手术切除的44例大肠癌肝转移患者的临床病理资料和蜡块标本,对所有入组病例进行随访。运用免疫组化Envision两步法检测C-erbB-2和VEGF在大肠癌肝转移灶、原发灶中的表达情况,并分别取15例正常大肠组织和肝脏切缘组织作对照,分析两者在肝转移灶和大肠癌原发灶中表达是否存在差异,探讨两者表达的规律性,分析其阳性表达与临床病理特征以及预后的关系。
研究结果:
1.C-erbB-2在大肠癌肝转移灶、肝脏切缘组织、大肠癌原发灶、正常大肠组织中的阳性率分别为38.64%、20.00%、31.25%、0,C-erbB-2在大肠癌中的阳性率显著高于正常大肠组织(P＜0.05),其在肝转移灶和肝脏切缘组织中的阳性率无显著统计学差异(P＞0.05)。VEGF在大肠癌肝转移灶、肝脏切缘组织、大肠癌原发灶、正常大肠组织中的阳性率分别为52.27%、40.00%、40.63%、0%,VEGF在大肠癌中的阳性率显著高于正常大肠组织(P＜0.05),而其在肝转移灶和肝脏切缘组织中的表达水平无显著差异(P＞0.05)
2.C-erbB-2和VEGF在大肠癌肝转移灶和原发灶中表达水平没有显著统计学差异(P＞0.05)。
3.C-erbB-2和VEGF两者在大肠癌肝转移灶和原发灶中的表达没有显著相关性(P＞0.05)。
4.VEGF在大肠癌肝转移灶和原发灶中表达存在一致性(P＜0.05),而c-erbB-2则没有一致性(P＞0.05)。
5.C-erbB-2阳性表达和肝转移灶数目和分布相关(P＜0.05),c-erbB-2阳性表达的患者和阴性表达的患者术后长期生存率没有显著差异(P＞0.05);VEGF的阳性率和肝转移灶的大小密切相关性(P＜0.05),VEGF阳性表达的患者肝转移灶切除术后长期生存率要低于VEGF无表达的患者(P＜0.05);C-erbB-2和VEGF联合检测可更有助于预后判断。
6.C-erbB-2在大肠癌肝转移灶和原发灶中的强阳性(++和+++)率较低,分别为11.36%(5/44)和9.73%(3/32),且C-erbB-2主要为胞浆阳性。
7.肝转移灶切缘处的肝组织中c-erbB-2和VEGF也有较高的表达水平,一部分患者肝转移灶切缘处的肝组织表达强度高于肿瘤组织。
8.单因素分析显示VEGF表达水平是预后的重要影响因素之一(P＜0.05),多因素分析显示VEGF并不是预后的一个独立影响因素(P＞0.05),而C-erbB-2阳性表达和预后没有显著相关性(P＞0.05)。
结论:
1.C-erbB-2和VEGF广泛表达于大肠癌肝转移灶和原发灶中,在肝脏切缘组织中两者也有较高表达,而在正常大肠组织中两者无表达。
2.C-erbB-2和VEGF在肝转移灶和原发灶中表达水平没有显著差异。
3.C-erbB-2和VEGF两者在大肠癌肝转移灶和原发灶中表达没有显著相关性。
4.VEGF在大肠癌肝转移灶中和原发灶中表达存在一致性,可以通过原发灶中VEGF的检测初步了解转移灶的表达情况,而c-erbB-2则在肝转移灶和原发灶中表达没有一致性。
5.C-erbB-2阳性表达和肝转移灶数目和分布相关,对预后没有判断价值;VEGF的阳性率和肝转移灶的大小密切相关性,阳性表达的患者肝转移灶术后长期生存率要低于VEGF无表达的患者;C-erbB-2和VEGF联合检测可更有助于预后判断。
6.C-erbB-2在大肠癌肝转移灶和原发灶中的强阳性率较低,且C-erbB-2主要为胞浆阳性。
Objective:
To investigate the expression of c-erbB-2 and VEGF protein expression in liver metastases and its corresponding primary colorectal cancer,to probe whether there are any regularity of its express in liver metastases and its primary cancer and to analyze whether there are any relationships of their expressions with clinicopathologic characteristics.Also we make a survival analysis to know what make a negative affect on survival after hepatectomy of liver metastases.
Methods:
Forty-four patients operated between 2000 and 2007 in Shanghai Cancer Hospital for colorectal cancer liver metastases were included.Clinicopathologic data were obtained from the patients' records.Immunohistological EnVision staining was used to detect the expression of c-erbB-2 and VEGF in Forty-four formalin-fixed liver metastases and thirty-two primary colorectal tumors,and 15 cases of normal colorectal tissues and liver tissues at surgical margin were taken as control research respectively. SPSS13.0 was used to analyze the correlation between c-erbB-2 and VEGF expression and clinical pathological parameters,to probe whether there are any correlation and conformity between c-erbB-2 and VEGF expression in liver metastases and its primary.
Results:
1.The positive percentages of c-erbB-2 in liver metastases、liver paracancerous tissues、colorectal cancer、normal colorectal tissues were 38.64%、20.00%、31.25%、0.The c-erbB-2 expression levels were significance higher in colorectal cancer than its normal tissues(P＜0.05),but their difference were not observe between liver metastases and its paracancerous tissues(P＞0.05).The positive percentages of VEGF were52.27%、40.00%、40.63%、0%in liver metastases、liver paracancerous tissues、colorectal cancer、normal colorectal tissues.The VEGF were significance higher in colorectal cancer than its normal tissues (P＜0.05),but no difference were observe between liver metastases and its paracancerous tissues(P＞0.05).
2.There is no significance different of c-erbB-2 and VEGF expression between liver metastases and primary cancer(P＞0.05).
3.There is no significance correlation between c-erbB-2 and VEGF expression in liver metastases and primary cancer(P＞0.05).
4.There is conformity of VEGF expression between liver metastases and its primary(P＜0.05),but not c-erbB-2(P＞0.05).
5.The expression of c-erbB-2 was positively correlated with distributes and numbers of liver metastases(P＜0.05),but have no relationship with overall survival after hepatectomy of liver metastases(P＞0.05),VEGF expression was association with maximal diameter of liver metastases and poor survival (P＜0.05).Combine analyses of c-erbB-2 and VEGF may show better predictive role after resection of liver metastases.
6.There is low strongly positive expression(++ and +++) of c-erbB-2 at liver metastases and colorectal cancer,which are 11.36%(5/44) and 9.73%(3/32) respectively,and mainly is cytoplasm positive.
7.There is also overexpression of c-erbB-2 and VEGF at liver resection margin tissues,and sometimes there are higher expressions of VEGF at paracancerous tissues than tumor itself.
8.Log rank test shows factors that VEGF expression have significance impact on overall survival after resection of liver metastases(P＜0.05),but Cox regression analyses didn't show it is an independent factors of survival(P＞0.05).
Conclusion:
1.C-erbB-2 and VEGF is common expressed in liver metastases and its primary cancer,c-erbB-2 and VEGF also are higher expression in liver resection margin tissuses,but not normal colorectal tissues.
2.There is no significance different between c-erbB-2 and VEGF expression in liver metastases and primary cancer.
3.There are no significance correlation between c-erbB-2 and VEGF expression in liver metastases and its primary cancer.
4.There is conformity of VEGF expression between liver metastases and its primary, we can roughly understand the liver expression of VEGF by check its primary colorectal cancer,but it is not the same of c-erbB-2.
5.C-erbB-2 expression was positively correlated with distributes and numbers of liver metastases,but have no relationship with overall survival after hepatectomy of liver metastases,VEGF expression was association with maximal diameter of liver metastases and poor survival.Combine analyses of c-erbB-2 and VEGF may show better predictive role after resection of liver metastases.
6.C-erbB-2 is mainly cytoplasm positive with low strongly positive.
引文
[1]Eugene A,Choi Steven E,Rodgers Syed A.et al.Hepatobiliary Cancers[A].In:Barry W,Feig David H,Berger George M.The M.D.Anderson Surgical Ontology Handbook.Fourth Edition[M].Texas:Lippincott Williams &Wilkins,2006:320-367.
[2]Kastrinakis WV,Ramchurren N,Maggard M,et al.K-ras status does not predict successful hepatic resection of colorectal cancer metastasis[J].Arch Surg,1995,130(1):9-15.
[3]Schuell B,Gruenberger T,Scheithauer W,et al.HER 2/neu protein expression in colorectal cancer[J].BMC Cancer,2006,8(6):123.
[4]Demirbas S,Sucullu I,Yildirim S,et al.Influence of the c-erbB-2,nm23,bcl-2 and p53 protein markers on colorectal cancer[J].Turk J Gastroenterol,2006,17(1):13-19.
[5]Kountourakis P,Pavlakis K,Psyrri A,et al.Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas[J].Cancer J,2006,12(3):229-236.
[6]Ishida H,Sadahiro S,Suzuki T,et al.c-erbB-2 protein expression and clinicopathologic features in colorectal cancer.Oncol Rep[J],2000,7(6):1229-1233.
[7]Yang JL,Ow KT,Russell PJ,et al.Higher expression of oncoproteins c-myc,c-erbB-2/neu,PCNA,and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors[J].Ann Surg Oncol,1996,3(6):574-579.
[8]Delektorskaia VV,Perevoshchikov AG,Kushlinskii NE Expression of nm23 and c-erbB-2 proteins in cells of primary colorectal cancer and its metastases[J].Arkh Patol,2003,65(5):11-15.
[9]肖秀英,周晓燕,孙孟红,等.MMP-2和C-erbB-2在散发性结直肠癌原发及转移灶中表达及意义[J].中国癌症杂志,2006,1(1):1-4.
[10]Kuwada SK,Scaife CL,Kuang J,et al.Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells[J].Int J Cancer,2004,109(2):291-301.
[11]Christine R,Raphalle B,Laetitia S,et al.The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein[J].Gastric Cancer,2005,8(4):249-252.
[12]TakahashiY,KitadaiY,Bucana CD,et al.Expression of vascular endothelial growth factor and its receptor,KDR,correlates with vascularity,metastasis,and proliferation of human colon cancer[J].Cancer Res,1995,55(18):3964-3968.
[13] Kang SM, Maeda K, Onoda N, et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis [J]. Int J Cancer, 1997,74(5):502-507.
[14] Takahashi Y,Tucker SL, Kitadai Y, et al.Vessel counts and expression of vascular endothelial growth factors prognostic factors in node-negative colon cancer[J].Arch Surg,1997,132(5):541-546.
[15] Cascinu S, Graziano F, Catalano V,et al. Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors[J].Clin Exp Metastasis, 2000,18(8):651-655.
[16] Tamura M, Oda M, Tsunezuka Y, et al.Vascular endothelial growth factor expression inmetastatic pulmonary tumor from colorectal carcinoma: utility as a prognostic factor[J].J Thorac Cardiovasc Surg, 2004,128(4): 517-522.
[17] Kuramochi H, Hayashi K, Uchida K,et al. Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer[J]. Clin Cancer Res, 2006,12(1):29-33.
[18] Klos KS,Wyszomierski SL,Sun M,et al.ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells [J]. Cancer Res,2006,66(4):2028-2037.
[19] Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinase down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors[J]. Am J Pathol, 1997, 151(6): 1523-1530.
[20] Yen L,You XL,A1 Moustafa AE,et al.Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis[ J]. Oncogene,2000,19(31): 3460-3469.
[21] Guan H, Jia SF, Zhou Z,et al. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing's sarcoma cells in vitro and in vivo[J]. Clin Cancer Res,2005,ll(5):2008-2017.
[22] Lee JS, Kim HS, Jung JJ,et al. Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression[J]. Gynecol Oncol, 2002,85(3):469-475.
[23] Do NY, Lim SC, Im TS. Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck[J].Oncol Rep,2004,12(2):229-237.
[24] Konecny GE, Meng YG, Untch M,et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients [J]. Clin Cancer Res, 2004; 10(5): 1706-1716.
[25] Wang S, Saboorian MH, Frenkel E,et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays[J]. J Clin Pathol, 2000,53(5):374-381.
[26] Scheurle D, Jahanzeb M, Aronsohn RS,et al. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test[J]. Anticancer Res,2000,20(3B):2091-2096
[27] Seliger B, Rongcun Y, Atkins D,et al. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes[J]. Int J Cancer,2000,87(3):349-359.
[28] Wang S,Saboorian MH,Frenkel E,et al. Laboratory assessment ofthe status of Her-2 /neu p rotein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization[J]. Clin Pathol,2000,53(5):374-381.
[29] Matsui Y,Inomata M,Tojigamori M,et al. Suppression of tumor growth in human gastric cancer with HER2 overexp ression by an anti-HER2 antibody in a murine model[J].Int J Oncol,2005,27(3): 681-685.
[30] Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies [J]. J Natl Cancer Inst, 1989, 81(8):570-576.
[31] Maehara Y, Kabashima A , Koga T,et al.Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma [J]. Surgery, 2000,128(3):408-416.
[32] Cascinu S, Staccioli MP, Gasparini G, et al. Expression of vascular endothelial growth factor can predict event free survival in stage II colon cancer [J]. Clin Cancer Res,2000,6 (7): 2803-2807.
[33] Seo Y, Baba H, Fukuda T,et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma [J]. Cancer, 2000, 88 (10):2239-2245.
[34] Ribero D, Wang H, Donadon M,et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases[J]. Cancer,2007,l 10(12):2761-2767.
[35] Reddy SK, Morse MA, Hurwitz HI,et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases[J]. J Am Coll Surg, 2008, 206(1):96-106.
[36]Yen L,You XL,A1 Moustafa AE,et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis[J].Oncogene,2000,19(31):3460-3469.
[37] Izumi Y,Xu L,di Tomaso E,et al.Tumour biology: herceptin acts as an anti-angiogenic cocktail[J]. Nature, 2002,416(6878):279-280.
[38] Finkenzeller G, Weindel K, Zimmermann W,et al. Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1[J]. Angiogenesis, 2004, 7(1):59-68.
[39] Ochs AM, Wong L, Kakani V,et al. Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival[J]. Clin Colorectal Cancer, 2004,4(4):262-267.
[40].Bevilacqua P, Barbareschi M, Verderio P, et al. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma—results of a multiparametric study [J]. Breast Cancer Res Treat, 1995, 36(2): 205-217.
[41].Inada K, Toi M, Hoshina S, Hayashi K, Tominaga T. Significance of tumor angiogenesis as an independent prognostic factor in axillarynode-negative breast cancer[J]. Gan To Kagaku Ryoho, 1995,22(Suppl. 1):59-65.
[42] Linderholm B, Andersson J, Lindh B,et al. Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment[J]. Eur J Cancer, 2004,40(1):33-42.
[1]Eugene A,Choi Steven E,Rodgers Syed A.et al.Hepatobiliary Cancers[A].In:Barry W,Feig David H,Berger George M.The M.D.Anderson Surgical Oncology Handbook.Fourth Edition[M].Texas:Lippincott Williams &Wilkins,2006:320-367.
[2]Cady B,Jenkins RL,Steele GD,et al.Surgical margin in hepatic resection for colorectal metastasis:a critical and improvable determinant of outcome[J].Ann Surg,1998,227(4):566-577.
[3]Malik HZ,Hamady ZZ,Adair R,et al.Prognostic influence of multiple hepatic metastases from colorectal cancer[J].Eur J Surg Oncol,2007,33(4):468-473.
[4]Johnson ST,Blitz M,Kneteman N,et al.Combined hepatic and inferior vena cava resection for colorectal metastases[J].J Gastrointest Surg,2006,10(2):220-226.
[5]Sugiura T,Nagino M,Ebata T,et al.Treatment of colorectal liver metastasis with biliary and portal vein tumor thrombi by hepatopancreatoduodenectomy[J].J Hepatobiliary Pancreat Surg,2006,13(3):256-259.
[6]Mazzoni G,Tocchi A,Miccini M,et al.Surgical treatment of liver metastases from colorectal cancer in elderly patients[J].Int J Colorectal Dis,2007,22(1):77-83.
[7]Leporrier J,Maurel J,Chiche L,et al.A population-based study of the incidence,management and prognosis of hepatic metastases from colorectal cancer[J].Br J Surg,2006,93(4):465-474.
[8]Thomas J,Hugh PG,Graeme J,et al.Hepatic metastases[A]:In:O.James Garden.Hepatobiliary and pancreatic surgery.Third Edition[M].Edinburgh:Elsevier limitied,2005;97-131.
[9]Pawlik TM,Scoggins CR,Zorzi D,et al.Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases[J].Ann Surg,2005,241(5):715-722.
[10]Hamady ZZ,Cameron IC,Wyatt J,et al.Resection margin in patients undergoing hepatectomy for colorectal liver metastasis:a critical appraisal of the lcm rule[J].Eur J Surg Oncol,2006,32(5):557-563.
[11]Hirai I,Kimura W,Fuse A,et al.Surgical management for metastatic liver tumors[J].Hepatogastroenterology,2006,53(71):757-763.
[12]Capussotti L,Ferrero A,Vigano L,et al.Major Liver Resections Synchronous with Colorectal Surgery[J].Ann Surg Oncol,2007,14(1):195-201.
[13]Martin R,Paty P,Fong Y,et al.Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis[J].J Am Coll Surg,2003,7(2):233-241.
[14]Peeters CF,de Waal RM,Wobbes T,et al.Outgrowth of human liver metastases after resection of the primary colorectal tumor:a shift in the balance between apoptosis and proliferation[J].Int J Cancer,2006,119(6):1249-1253.
[15]Capussotti L,Muratore A,Mulas MM,et al.Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases[J].Br J Surg,2006,93(8):1001-1006.
[16]Lambert LA,Colacchio TA,Barth RJ Jr.Interval hepatic resection of colorectal metastases improves patient selection[J].Arch Surg,2000,135(4):473-479.
[17]Zaniboni A,Torri V,Tinazzi A,et al.Neoadjuvant oxaliplatin-based chemotherapy for liver metastases from colorectal cancer.An Italian survey[J].Tumori,2005,91(5):383-387.
[18]Aloia T,Sebagh M,Plasse M,et al.Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases[J].J Clin Oncol,2006,24(31):4983-4990.
[19]Tanaka K,Shimada H,Ueda M,et al.Perioperative complications after hepatectomy with or without intra-arterial chemotherapy for bilobar colorectal cancer liver metastases[J].Surgery,2006,139(5):599-607.
[20]Vauthey JN,Pawlik TM,Ribero D,et al.Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases[J].J Clin Oncol,2006,24(13):2065-2072.
[21]李清国.术前选择性门静脉栓塞在大肠癌肝转移患者中的应用[J].国际肿瘤学杂志,2006,33(11):845-848.
[22]Beal IK,Anthony S,Papadopoulou A,et al.Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy[J].Br J Radiol,2006,79(942):473-8.
[23]Goere D,Farges O,Leporrier J,et al.Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction[J].J Gastrointest Surg,2006,10(3):365-70.